Literature DB >> 16830191

Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.

Carolina Rodrigues Costa1, Janine Aquino de Lemos, Xisto Sena Passos, Crystiane Rodrigues de Araújo, Ana Joaquina Cohen, Lúcia Kioko Hasimoto E Souza, Maria do Rosário Rodrigues Silva.   

Abstract

In this study, we investigated the yeasts colonization of genus Candida, including C. dubliniensis, isolated of HIV-infected patients oral cavities and we accessed in vitro susceptibility pattern of the Candida isolates to four antifungal agents. Out of 99 patients investigated, 62 (62.6%) were colonized with yeasts. C. albicans was the prevailing species (50%). C. dubliniensis isolates were not recovered in our study. We verified that 8.1% of the yeasts isolated were resistant to fluconazole, 8.1% to itraconazole and 3.2% to voriconazole. The isolates demonstrated very low voriconazole MICs, in which 79% (49/62) presented values of 0.015 mug/ml. All Candida isolates were susceptible to amphotericin B. The results reported here showed that although C. albicans continues to be present in one-half of oral Candida carriage of HIV-infected patients, Candida non-albicans species are increasing among these patients. Besides, the findings of resistant isolates endorse the role of antifungal susceptibility testing whenever antifungal treatment with azoles is planned.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830191     DOI: 10.1007/s11046-006-0032-y

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  33 in total

1.  Detection of Candida dubliniensis in oropharyngeal samples of Turkish HIV-positive patients.

Authors:  A Tekeli; E Koyuncu; I Dolapci; G S Guven; G O Sahin; O Uzun
Journal:  Mycoses       Date:  2005-05       Impact factor: 4.377

2.  Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States.

Authors:  T F Meiller; M A Jabra-Rizk; A a Baqui; J I Kelley; V I Meeks; W G Merz; W A Falkler
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1999-11

3.  Isolation of C. dubliniensis from insulin-using diabetes mellitus patients.

Authors:  A M Willis; W A Coulter; D J Sullivan; D C Coleman; J R Hayes; P M Bell; P J Lamey
Journal:  J Oral Pathol Med       Date:  2000-02       Impact factor: 4.253

4.  Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.

Authors:  M Cuenca-Estrella; E Mellado; T M Díaz-Guerra; A Monzón; J L Rodríguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

5.  Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae.

Authors:  M A Pfaller; S A Messer; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1994-11       Impact factor: 2.803

6.  Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation.

Authors:  J F Meis; M Ruhnke; B E De Pauw; F C Odds; W Siegert; P E Verweij
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

7.  Fluconazole susceptibility of Brazilian Candida isolates assessed by a disk diffusion method.

Authors:  Arnaldo L Colombo; Daniel Da Matta; Leila Paula De Almeida; Robert Rosas
Journal:  Braz J Infect Dis       Date:  2002-06       Impact factor: 1.949

8.  Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.

Authors:  Monika Sojakova; Denisa Liptajova; Miroslav Borovsky; Julius Subik
Journal:  Mycopathologia       Date:  2004-02       Impact factor: 2.574

9.  Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals.

Authors:  D J Sullivan; T J Westerneng; K A Haynes; D E Bennett; D C Coleman
Journal:  Microbiology       Date:  1995-07       Impact factor: 2.777

Review 10.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

View more
  12 in total

1.  Mucosal Candida infection and colonisation as well as associated risk factors in solid organ transplant recipients.

Authors:  L Antoniewicz; D Relijc; C Poitschek; E Presterl; A Geusau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-02       Impact factor: 3.267

2.  Evaluation of antifungal activity of medicinal plant extracts against oral Candida albicans and proteinases.

Authors:  José Francisco Höfling; Rita Cássia Mardegan; Paula Cristina Anibal; Vivian Fernandes Furletti; Mary Ann Foglio
Journal:  Mycopathologia       Date:  2011-03-16       Impact factor: 2.574

3.  Yeast oropharyngeal colonization in human immunodeficiency virus-infected patients in central taiwan.

Authors:  Mao-Wang Ho; Yun-Liang Yang; Chih-Chao Lin; Chih-Yu Chi; Hui-Ting Chen; Po-Chang Lin; Li-Yun Hsieh; Chia-Hui Chou; Wen-Li Chu; Chiou-Pyng Wu; Tsai-Ling Lauderdale; Hsiu-Jung Lo
Journal:  Mycopathologia       Date:  2014-05-08       Impact factor: 2.574

4.  Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis.

Authors:  You Bum Song; Moo Kyu Suh; Gyoung Yim Ha; Heesoo Kim
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

5.  Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China.

Authors:  Yu-Ye Li; Wen-Ying Chen; Xia Li; Hong-Bin Li; Hui-Qin Li; Li Wang; Li He; Xin-Ping Yang; Xi-Cheng Wang; Yun-Li Huang; Yong-Gang Yao
Journal:  BMC Infect Dis       Date:  2013-01-28       Impact factor: 3.090

6.  Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis.

Authors:  Omar J M Hamza; Mecky I N Matee; Mainen J Moshi; Elison N M Simon; Ferdinand Mugusi; Frans H M Mikx; Wim H van Palenstein Helderman; Antonius J M M Rijs; André J A M van der Ven; Paul E Verweij
Journal:  BMC Microbiol       Date:  2008-08-12       Impact factor: 3.605

7.  Conventional and alternative antifungal therapies to oral candidiasis.

Authors:  Paula Cristina Anibal; Janaina de Cássia Orlandi Sardi; Iza Teixeira Alves Peixoto; Julianna Joanna de Carvalho Moraes; José Francisco Höfling
Journal:  Braz J Microbiol       Date:  2010-12-01       Impact factor: 2.476

8.  Antifungal suscepitibility profile of candida spp. oral isolates obtained from denture wearers.

Authors:  J P Lyon; L M Moreira; M A G Cardoso; J Saade; M A Resende
Journal:  Braz J Microbiol       Date:  2008-12-01       Impact factor: 2.476

9.  Candida Species Prevalence Profile in HIV Seropositive Patients from a Major Tertiary Care Hospital in New Delhi, India.

Authors:  Monika Maheshwari; Ravinder Kaur; Sanjim Chadha
Journal:  J Pathog       Date:  2016-03-22

10.  Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis.

Authors:  Birhan Moges; Adane Bitew; Aster Shewaamare
Journal:  Int J Microbiol       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.